Aug. 20, 2026
Research led by UNC doctors and published Aug. 13 by the Centers for Disease Control and Prevention...
Read MoreMay 1, 2026
Academic research leaders across the country, including UNC Vice Chancellor for Research Penny Gordon-Larsen, have...
Read MoreNov. 19, 2025
Jeffrey Bardzell expected to remain the dean of the School of Information and Library Science...
Read MoreA research study involving thousands of volunteers has yielded a new test that can determine which patients can receive hormonal therapy alone to successfully treat ER-positive HER2-negative breast cancer — the most common form of the disease — without chemotherapy.
Chuck Perou, a cancer geneticist at the UNC Lineberger Comprehensive Cancer Center, led research to discover at least five specific subtypes of breast cancer. The guiding principle of this work was that if doctors could learn more about the molecular makeup of tumors, they could devise more precise therapeutic options for patients, instead of one-size-fits-all treatments.
From that research, Perou and clinical colleagues created a test called Prosigna, which analyzes tumor samples and uses a machine learning algorithm to provide doctors with insight into how a patient’s early stage cancer may develop or change over time. The test also scores a patient’s risk of cancer recurrence.
For nearly 20 years, researchers used Prosigna while treating more than 4,400 breast cancer patients in the United Kingdom, Norway, Sweden, Australia, New Zealand and Thailand. The clinical trial results, announced this summer at the American Society of Clinical Oncology conference, showed that 68 percent of ER-positive HER2-Negative breast cancer patients could safely forgo chemotherapy — an often debilitating treatment — without sacrificing positive health outcomes.
Prosigna proved equally effective for premenopausal women and patients with multiple cancerous lymph nodes, which showed that tumor biology could guide chemotherapy decisions for even complex cases.
Following the clinical trial and commercialization of the test, cancer doctors in the United States and the United Kingdom can now order the Prosigna test to predict which high-risk patients can safely avoid chemotherapy and its lasting side effects.